## Multiple Myeloma

## Treatment with Bisphosphonates

This measure is to be reported for all patients aged 18 years and older with multiple myeloma, not in remission - a minimum of once per reporting period.

## Measure description

Percentage of patients aged 18 years and older with a diagnosis of multiple myeloma, not in remission, who were prescribed ${ }^{1}$ or received intravenous bisphosphonate therapy within the 12 month reporting period

## What will you need to report for each patient with multiple myeloma for this measure?

If you select this measure for reporting, you will report:

- Whether or not you prescribed or the patient received intravenous bisphosphonate therapy ${ }^{2}$


## What if this process or outcome of care is not appropriate for your patient?

There may be times when it is not appropriate to prescribe intravenous bisphosphonate therapy, due to:

- Medical reasons (eg, patients who do not have bone disease, patients with dental disease, patients with renal insufficiency) OR
- Patient reasons (eg, patient declined, economic, social, religious, other patient reason)

In these cases, you will need to indicate which reason applies, and specify the reason on the worksheet and in the medical chart. The office/billing staff will then report a code with a modifier that represents these valid reasons (also called exclusions).

[^0][^1]
[^0]:    1"Prescribed" includes patients who are currently receiving medication(s) that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.
    ${ }^{2}$ For the purpose of this measure bisphosphonate therapy includes the following medications: pamidronate and zoledronate.

[^1]:    PQRI 2009 Measure 69, Effective Date 01/01/2009
    © 2006-7 American Medical Association and American Society of Hematology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
    (Disclaimers, Copyright and other Notices indicated on the Coding Specifications document are incorporated by reference)

